The Experts below are selected from a list of 42 Experts worldwide ranked by ideXlab platform

Michele Carbone - One of the best experts on this subject based on the ideXlab platform.

  • A cytokeratin- and calretinin-negative staining sarcomatoid malignant Mesothelioma.
    Anticancer Research, 2004
    Co-Authors: Michael G. Hurtuk, Michele Carbone
    Abstract:

    Malignant Mesothelioma, or Mesothelioma, is a mesothelial-based malignancy that may occur in the pleura, pericardium and Peritoneum. Mesothelioma is a very aggressive cancer with limited treatment, and a median survival of about 1 year. At times, the diagnosis of Mesothelioma may be problematic. The final diagnosis of Mesothelioma relies on histology and often is dependent upon immunohistochemistry. It is generally assumed that Mesotheliomas must stain positive for cytokeratin and calretinin and negative staining for these markers would rule out the diagnosis. We encountered a patient with a pleural-based, cytokeratin- and calretinin-negative sarcomatoid malignancy. These negative stainings would rule out the diagnosis of Mesothelioma but, after careful consideration of the patient's clinical records, and additional histological and immunohistochemical studies, we conclude that this patient suffered from Mesothelioma of the sarcomatoid type.

  • A cytokeratin- and calretinin-negative staining sarcomatoid malignant Mesothelioma.
    Anticancer Research, 2004
    Co-Authors: Michael G. Hurtuk, Michele Carbone
    Abstract:

    Malignant Mesothelioma, or Mesothelioma, is a mesothelial-based malignancy that may occur in the pleura, pericardium and Peritoneum. Mesothelioma is a very aggressive cancer with limited treatment, and a median survival of about 1 year. At times, the diagnosis of Mesothelioma may be problematic. The final diagnosis of Mesothelioma relies on histology and often is dependent upon immunohistochemistry. It is generally assumed that Mesotheliomas must stain positive for cytokeratin and calretinin and negative staining for these markers would rule out the diagnosis. We encountered a patient with a pleural-based, cytokeratin- and calretinin- negative sarcomatoid malignancy. These negative stainings would rule out the diagnosis of Mesothelioma but, after careful consideration of the patient's clinical records, and additional histological and immunohistochemical studies, we conclude that this patient suffered from Mesothelioma of the sarcomatoid type. Mesothelial cells form the lining of the pericardial, pleural and peritoneal cavities. They are among the most

Andrew M. Lowy - One of the best experts on this subject based on the ideXlab platform.

  • A Novel Tool for Predicting Major Complications After Cytoreductive Surgery with Hyperthermic Intraperitoneal Chemotherapy
    Annals of Surgical Oncology, 2016
    Co-Authors: Joel M. Baumgartner, Thomas G. Kwong, Grace L. Ma, Karen Messer, Kaitlyn J. Kelly, Andrew M. Lowy
    Abstract:

    Background Cytoreductive surgery with hyperthermic intraperitoneal chemotherapy (CRS-HIPEC) has an emerging role in the treatment of peritoneal malignancies. The CRS-HIPEC approach has known treatment-related toxicities. This study sought to determine the predictors of major postoperative complications after CRS-HIPEC in a high-volume center. Methods From a single-institution database, this study investigated complications experienced by patients undergoing CRS-HIPEC. Multiple preoperative and operative factors were analyzed for their ability to predict 60-day Clavien grade 3 and greater (major) complications by logistic regression. A predictive model was created from preoperative factors using multivariate logistic regression. The model was tested by Akaike’s information criterion, the Hosmer and Lemeshow Goodness-of-Fit Test, the receiver operating characteristic, and the Youden Index. Results The study evaluated 247 patients undergoing CRS-HIPEC. The primary tumor site was the appendix in 166 cases (67.2 %), the colorectal area in 51 cases (20.6 %), the Peritoneum (Mesothelioma) in 22 cases (8.9 %), the ovary in 5 cases (2 %), and the small bowel in 3 cases (1.2 %). The median peritoneal cancer index was 14 (range 0–29), and 235 patients (95.1 %) had a complete (CC-0/1) cytoreduction. Major complications occurred for 41 patients (16.6 %), classified as grade 3 in 33 cases (13.4 %), grade 4 in 5 cases (2 %), and grade 5 (deaths) in 3 cases (1.2 %). The factors predictive of major complications in the multivariate analysis were a Charlson Comorbidity Index (CCI) score higher than 0 [odds ratio (OR), 2.505; p = 0.035], presence of preoperative symptoms (OR 1.951; p = 0.064), and prior resection status [no resection or prior CRS-HIPEC (OR 2.087) vs. prior resection without CRS-HIPEC (OR 3.209); p = 0.046]. These variables were used to create a tool predictive of postoperative complications. Conclusion Presence of symptoms, CCI, and prior resection status predict major complications and define a low-risk population after CRS-HIPEC.

Michael G. Hurtuk - One of the best experts on this subject based on the ideXlab platform.

  • A cytokeratin- and calretinin-negative staining sarcomatoid malignant Mesothelioma.
    Anticancer Research, 2004
    Co-Authors: Michael G. Hurtuk, Michele Carbone
    Abstract:

    Malignant Mesothelioma, or Mesothelioma, is a mesothelial-based malignancy that may occur in the pleura, pericardium and Peritoneum. Mesothelioma is a very aggressive cancer with limited treatment, and a median survival of about 1 year. At times, the diagnosis of Mesothelioma may be problematic. The final diagnosis of Mesothelioma relies on histology and often is dependent upon immunohistochemistry. It is generally assumed that Mesotheliomas must stain positive for cytokeratin and calretinin and negative staining for these markers would rule out the diagnosis. We encountered a patient with a pleural-based, cytokeratin- and calretinin-negative sarcomatoid malignancy. These negative stainings would rule out the diagnosis of Mesothelioma but, after careful consideration of the patient's clinical records, and additional histological and immunohistochemical studies, we conclude that this patient suffered from Mesothelioma of the sarcomatoid type.

  • A cytokeratin- and calretinin-negative staining sarcomatoid malignant Mesothelioma.
    Anticancer Research, 2004
    Co-Authors: Michael G. Hurtuk, Michele Carbone
    Abstract:

    Malignant Mesothelioma, or Mesothelioma, is a mesothelial-based malignancy that may occur in the pleura, pericardium and Peritoneum. Mesothelioma is a very aggressive cancer with limited treatment, and a median survival of about 1 year. At times, the diagnosis of Mesothelioma may be problematic. The final diagnosis of Mesothelioma relies on histology and often is dependent upon immunohistochemistry. It is generally assumed that Mesotheliomas must stain positive for cytokeratin and calretinin and negative staining for these markers would rule out the diagnosis. We encountered a patient with a pleural-based, cytokeratin- and calretinin- negative sarcomatoid malignancy. These negative stainings would rule out the diagnosis of Mesothelioma but, after careful consideration of the patient's clinical records, and additional histological and immunohistochemical studies, we conclude that this patient suffered from Mesothelioma of the sarcomatoid type. Mesothelial cells form the lining of the pericardial, pleural and peritoneal cavities. They are among the most

Joel M. Baumgartner - One of the best experts on this subject based on the ideXlab platform.

  • A Novel Tool for Predicting Major Complications After Cytoreductive Surgery with Hyperthermic Intraperitoneal Chemotherapy
    Annals of Surgical Oncology, 2016
    Co-Authors: Joel M. Baumgartner, Thomas G. Kwong, Grace L. Ma, Karen Messer, Kaitlyn J. Kelly, Andrew M. Lowy
    Abstract:

    Background Cytoreductive surgery with hyperthermic intraperitoneal chemotherapy (CRS-HIPEC) has an emerging role in the treatment of peritoneal malignancies. The CRS-HIPEC approach has known treatment-related toxicities. This study sought to determine the predictors of major postoperative complications after CRS-HIPEC in a high-volume center. Methods From a single-institution database, this study investigated complications experienced by patients undergoing CRS-HIPEC. Multiple preoperative and operative factors were analyzed for their ability to predict 60-day Clavien grade 3 and greater (major) complications by logistic regression. A predictive model was created from preoperative factors using multivariate logistic regression. The model was tested by Akaike’s information criterion, the Hosmer and Lemeshow Goodness-of-Fit Test, the receiver operating characteristic, and the Youden Index. Results The study evaluated 247 patients undergoing CRS-HIPEC. The primary tumor site was the appendix in 166 cases (67.2 %), the colorectal area in 51 cases (20.6 %), the Peritoneum (Mesothelioma) in 22 cases (8.9 %), the ovary in 5 cases (2 %), and the small bowel in 3 cases (1.2 %). The median peritoneal cancer index was 14 (range 0–29), and 235 patients (95.1 %) had a complete (CC-0/1) cytoreduction. Major complications occurred for 41 patients (16.6 %), classified as grade 3 in 33 cases (13.4 %), grade 4 in 5 cases (2 %), and grade 5 (deaths) in 3 cases (1.2 %). The factors predictive of major complications in the multivariate analysis were a Charlson Comorbidity Index (CCI) score higher than 0 [odds ratio (OR), 2.505; p = 0.035], presence of preoperative symptoms (OR 1.951; p = 0.064), and prior resection status [no resection or prior CRS-HIPEC (OR 2.087) vs. prior resection without CRS-HIPEC (OR 3.209); p = 0.046]. These variables were used to create a tool predictive of postoperative complications. Conclusion Presence of symptoms, CCI, and prior resection status predict major complications and define a low-risk population after CRS-HIPEC.

Kaitlyn J. Kelly - One of the best experts on this subject based on the ideXlab platform.

  • A Novel Tool for Predicting Major Complications After Cytoreductive Surgery with Hyperthermic Intraperitoneal Chemotherapy
    Annals of Surgical Oncology, 2016
    Co-Authors: Joel M. Baumgartner, Thomas G. Kwong, Grace L. Ma, Karen Messer, Kaitlyn J. Kelly, Andrew M. Lowy
    Abstract:

    Background Cytoreductive surgery with hyperthermic intraperitoneal chemotherapy (CRS-HIPEC) has an emerging role in the treatment of peritoneal malignancies. The CRS-HIPEC approach has known treatment-related toxicities. This study sought to determine the predictors of major postoperative complications after CRS-HIPEC in a high-volume center. Methods From a single-institution database, this study investigated complications experienced by patients undergoing CRS-HIPEC. Multiple preoperative and operative factors were analyzed for their ability to predict 60-day Clavien grade 3 and greater (major) complications by logistic regression. A predictive model was created from preoperative factors using multivariate logistic regression. The model was tested by Akaike’s information criterion, the Hosmer and Lemeshow Goodness-of-Fit Test, the receiver operating characteristic, and the Youden Index. Results The study evaluated 247 patients undergoing CRS-HIPEC. The primary tumor site was the appendix in 166 cases (67.2 %), the colorectal area in 51 cases (20.6 %), the Peritoneum (Mesothelioma) in 22 cases (8.9 %), the ovary in 5 cases (2 %), and the small bowel in 3 cases (1.2 %). The median peritoneal cancer index was 14 (range 0–29), and 235 patients (95.1 %) had a complete (CC-0/1) cytoreduction. Major complications occurred for 41 patients (16.6 %), classified as grade 3 in 33 cases (13.4 %), grade 4 in 5 cases (2 %), and grade 5 (deaths) in 3 cases (1.2 %). The factors predictive of major complications in the multivariate analysis were a Charlson Comorbidity Index (CCI) score higher than 0 [odds ratio (OR), 2.505; p = 0.035], presence of preoperative symptoms (OR 1.951; p = 0.064), and prior resection status [no resection or prior CRS-HIPEC (OR 2.087) vs. prior resection without CRS-HIPEC (OR 3.209); p = 0.046]. These variables were used to create a tool predictive of postoperative complications. Conclusion Presence of symptoms, CCI, and prior resection status predict major complications and define a low-risk population after CRS-HIPEC.